0
0
A new meta-analysis suggests that continuing metformin treatment throughout the first trimester of pregnancy may significantly reduce the risk of miscarriage and improve clinical pregnancy rates in women with polycystic ovary syndrome (PCOS). The findings offer renewed hope for women with PCOS, a condition known to increase the risk of both insulin resistance and pregnancy complications.
Study Details and Key Findings
Researchers conducted a systematic review and meta-analysis of 12 randomized controlled trials, including 1,708 women from 14 countries across five continents. The analysis compared women who started metformin before conception and continued through at least a positive pregnancy test, with those who stopped the medication at pregnancy confirmation or received a placebo/no treatment.
Key outcomes included:
-
Women who continued metformin through the first trimester had a higher clinical pregnancy rate (odds ratio [OR], 1.57) and a potential reduction in miscarriage risk (OR, 0.64) compared with placebo or no treatment.
-
Stopping metformin at pregnancy confirmation was associated with a higher clinical pregnancy rate (OR, 1.35) but a suggested increase in miscarriage risk (OR, 1.46) compared with placebo or no treatment.
-
Indirect comparisons favored continuing metformin through the first trimester for all outcomes, including clinical pregnancy, miscarriage, and live birth rates.
Expert Perspective
The study authors noted that women with PCOS face a fivefold increased risk of developing insulin resistance and subsequent type 2 diabetes. Insulin resistance itself is independently linked to a higher risk of miscarriage. Metformin works by reducing gluconeogenesis and lipogenesis while enhancing glucose uptake, thereby lowering insulin resistance and potentially improving pregnancy outcomes.
Implications for Practice
While the evidence is graded as low to moderate quality, the findings suggest that continuing metformin during the first trimester could offer meaningful benefits for women with PCOS hoping to achieve and maintain a healthy pregnancy.
“Women receiving preconception metformin continued throughout the first trimester had higher clinical pregnancy rates and potential reduction in miscarriage,” the study concludes.
Disclaimer
This article summarizes findings from a recent meta-analysis and does not constitute medical advice. Patients should consult their healthcare provider before making any changes to their medication regimen, as individual risks and benefits may vary.
